CN106163529A - 包含无定形索非布韦的固体组合物 - Google Patents
包含无定形索非布韦的固体组合物 Download PDFInfo
- Publication number
- CN106163529A CN106163529A CN201580018422.4A CN201580018422A CN106163529A CN 106163529 A CN106163529 A CN 106163529A CN 201580018422 A CN201580018422 A CN 201580018422A CN 106163529 A CN106163529 A CN 106163529A
- Authority
- CN
- China
- Prior art keywords
- weight
- sofosbuvir
- solid
- suo feibuwei
- solvent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Oc1ccccc1 Chemical compound Oc1ccccc1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- KHFWXDGTRHRELO-ADUGICMHSA-N CC(C)OC(C(N(c(cccc1)c1O)OC[C@H]([C@H]([C@@]1(C)F)O)O[C@H]1N(C(N1)O)C=CC1=O)=C)=O Chemical compound CC(C)OC(C(N(c(cccc1)c1O)OC[C@H]([C@H]([C@@]1(C)F)O)O[C@H]1N(C(N1)O)C=CC1=O)=C)=O KHFWXDGTRHRELO-ADUGICMHSA-N 0.000 description 1
- LWMJCJFOPLAQLG-PHBZWQRYSA-N CC(C)OC(C(NP(OC[C@H]([C@H]([C@@]1(C)F)O)O[C@H]1N(C=CC(N1)=O)C1=O)(Oc1ccccc1)=O)=C)=O Chemical compound CC(C)OC(C(NP(OC[C@H]([C@H]([C@@]1(C)F)O)O[C@H]1N(C=CC(N1)=O)C1=O)(Oc1ccccc1)=O)=C)=O LWMJCJFOPLAQLG-PHBZWQRYSA-N 0.000 description 1
- TTZHDVOVKQGIBA-IAAJYNJHSA-N CC(C)OC([C@H](C)NP(OC[C@H]([C@H]([C@@]1(C)F)O)O[C@H]1N(C=CC(N1)=O)C1=O)(Oc1ccccc1)=O)=O Chemical compound CC(C)OC([C@H](C)NP(OC[C@H]([C@H]([C@@]1(C)F)O)O[C@H]1N(C=CC(N1)=O)C1=O)(Oc1ccccc1)=O)=O TTZHDVOVKQGIBA-IAAJYNJHSA-N 0.000 description 1
- 0 C[C@@]1([C@](*(C=CC(*2(C)C)=O)C2=O)O[C@](COC)C1)N Chemical compound C[C@@]1([C@](*(C=CC(*2(C)C)=O)C2=O)O[C@](COC)C1)N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/22—Amides of acids of phosphorus
- C07F9/222—Amides of phosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C07H1/06—Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Virology (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14163434 | 2014-04-03 | ||
| EP14163434.5 | 2014-04-03 | ||
| PCT/EP2015/057411 WO2015150561A2 (en) | 2014-04-03 | 2015-04-02 | Solid composition comprising amorphous sofosbuvir |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106163529A true CN106163529A (zh) | 2016-11-23 |
Family
ID=50397065
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201580018422.4A Withdrawn CN106163529A (zh) | 2014-04-03 | 2015-04-02 | 包含无定形索非布韦的固体组合物 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US10493089B2 (https=) |
| EP (1) | EP3125868A2 (https=) |
| JP (1) | JP2017512811A (https=) |
| KR (1) | KR20160142342A (https=) |
| CN (1) | CN106163529A (https=) |
| AU (1) | AU2015239018A1 (https=) |
| CA (1) | CA2943574A1 (https=) |
| MX (2) | MX2016012934A (https=) |
| RU (1) | RU2016142819A (https=) |
| WO (1) | WO2015150561A2 (https=) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108210509A (zh) * | 2016-12-13 | 2018-06-29 | 南京圣和药业股份有限公司 | 新的核苷氨基磷酸脂化合物的组合物及其制备方法 |
| CN110325192A (zh) * | 2017-06-30 | 2019-10-11 | 伊兹瓦里诺帕玛有限责任公司 | 具有抗hiv活性的药物组合物 |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3524234B1 (en) | 2014-06-13 | 2020-12-09 | Ratiopharm GmbH | Solid state forms of sofosbuvir |
| WO2016038542A2 (en) * | 2014-09-10 | 2016-03-17 | Mylan Laboratories Limited | Polymorphic forms of sofosbuvir |
| CZ2015443A3 (cs) * | 2015-06-26 | 2017-01-04 | Zentiva, K.S. | Farmaceutická formulace sofosbuviru |
| US20180271890A1 (en) * | 2015-10-07 | 2018-09-27 | Sandoz Ag | Solid Pharmaceutical Composition Comprising Amorphous Sofosbuvir |
| CZ2016257A3 (cs) * | 2016-05-05 | 2017-11-15 | Zentiva, K.S. | Amorfní forma sofosbuviru, způsob její přípravy a její stabilizace |
| CN106083963A (zh) * | 2016-06-08 | 2016-11-09 | 上海现代制药海门有限公司 | 一种索非布韦晶型6的制备方法 |
| RU2019106294A (ru) * | 2016-08-12 | 2020-09-21 | Сандоз Аг | Твердая фармацевтическая композиция, содержащая аморфный софосбувир |
| CZ2016553A3 (cs) | 2016-09-09 | 2018-03-21 | Zentiva, K.S. | Pevná farmaceutická dávková forma obsahující sofosbuvir |
| WO2018078536A1 (en) | 2016-10-26 | 2018-05-03 | Lupin Limited | Stable solid dispersion of sofosbuvir and process for preparation thereof |
| WO2019134971A1 (en) * | 2018-01-04 | 2019-07-11 | Sandoz Ag | Encapsulated particles comprising a pharmaceutically active ingredient |
| JP7124107B2 (ja) | 2018-10-05 | 2022-08-23 | 富士化学工業株式会社 | 多孔性シリカ粒子組成物 |
| CN111040010A (zh) * | 2019-12-23 | 2020-04-21 | 上海红蓝医药科技有限公司 | 一种索非布韦中间体的合成方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020006951A1 (en) * | 1999-12-08 | 2002-01-17 | Hageman Michael J. | Solid-state form of celecoxib having enhanced bioavailability |
| WO2013101550A1 (en) * | 2011-12-29 | 2013-07-04 | Abbvie Inc. | Solid compositions comprising an hcv inhibitor |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1200262C (zh) | 2003-01-10 | 2005-05-04 | 清华大学 | 测量粉末吸附气体量的方法和设备 |
| WO2010017965A2 (en) | 2008-08-11 | 2010-02-18 | Merck Serono S.A. | SOLID LIPID MICROCAPSULES CONTAINING hGH |
| TWI598358B (zh) | 2009-05-20 | 2017-09-11 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
| PT2609923T (pt) | 2010-03-31 | 2017-08-30 | Gilead Pharmasset Llc | Processo para a cristalização de 2-(((s)- (perfluorofenoxi)(fenoxi)fosforil)amino)propanoato de (s)-isopropilo |
| CA2862229A1 (en) * | 2011-12-30 | 2013-07-04 | Chevron U.S.A. Inc. | Process, method, and system for removing heavy metals from fluids |
| EA201690473A1 (ru) * | 2013-08-27 | 2017-03-31 | ГАЙЛИД ФАРМАССЕТ ЭлЭлСи | Комбинированный состав двух противовирусных соединений |
-
2015
- 2015-04-02 KR KR1020167030432A patent/KR20160142342A/ko not_active Withdrawn
- 2015-04-02 JP JP2016560461A patent/JP2017512811A/ja not_active Ceased
- 2015-04-02 CN CN201580018422.4A patent/CN106163529A/zh not_active Withdrawn
- 2015-04-02 WO PCT/EP2015/057411 patent/WO2015150561A2/en not_active Ceased
- 2015-04-02 AU AU2015239018A patent/AU2015239018A1/en not_active Abandoned
- 2015-04-02 CA CA2943574A patent/CA2943574A1/en not_active Abandoned
- 2015-04-02 EP EP15713526.0A patent/EP3125868A2/en not_active Withdrawn
- 2015-04-02 RU RU2016142819A patent/RU2016142819A/ru not_active Application Discontinuation
- 2015-04-02 US US15/129,149 patent/US10493089B2/en not_active Expired - Fee Related
- 2015-04-02 MX MX2016012934A patent/MX2016012934A/es unknown
-
2016
- 2016-09-30 MX MX2019009842A patent/MX2019009842A/es unknown
-
2019
- 2019-08-23 US US16/550,057 patent/US20190381085A1/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020006951A1 (en) * | 1999-12-08 | 2002-01-17 | Hageman Michael J. | Solid-state form of celecoxib having enhanced bioavailability |
| WO2013101550A1 (en) * | 2011-12-29 | 2013-07-04 | Abbvie Inc. | Solid compositions comprising an hcv inhibitor |
Non-Patent Citations (1)
| Title |
|---|
| VAIBHAV I. PATEL, ET AL.: "Evaluation of Colloidal Solid Dispersions: Physiochemical Considerations and In Vitro Release Profile", 《AAPS PHARMSCITECH》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108210509A (zh) * | 2016-12-13 | 2018-06-29 | 南京圣和药业股份有限公司 | 新的核苷氨基磷酸脂化合物的组合物及其制备方法 |
| CN110325192A (zh) * | 2017-06-30 | 2019-10-11 | 伊兹瓦里诺帕玛有限责任公司 | 具有抗hiv活性的药物组合物 |
Also Published As
| Publication number | Publication date |
|---|---|
| RU2016142819A (ru) | 2018-05-10 |
| MX2016012934A (es) | 2016-12-07 |
| CA2943574A1 (en) | 2015-10-08 |
| AU2015239018A1 (en) | 2016-10-13 |
| WO2015150561A2 (en) | 2015-10-08 |
| EP3125868A2 (en) | 2017-02-08 |
| RU2016142819A3 (https=) | 2018-05-10 |
| WO2015150561A3 (en) | 2016-01-28 |
| JP2017512811A (ja) | 2017-05-25 |
| MX2019009842A (es) | 2019-10-22 |
| US10493089B2 (en) | 2019-12-03 |
| US20190381085A1 (en) | 2019-12-19 |
| US20170100422A1 (en) | 2017-04-13 |
| KR20160142342A (ko) | 2016-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106163529A (zh) | 包含无定形索非布韦的固体组合物 | |
| JP5283632B2 (ja) | ベンズイミダゾール−７−カルボキシレート誘導体およびｐＨ調整剤を含有する固形医薬組成物 | |
| TWI405574B (zh) | 藥學固體製劑及其製造方法 | |
| EP3606511A1 (en) | Pharmaceutical composition comprising lenvatinib mesylate | |
| WO2008027600A2 (en) | Imatinib compositions | |
| KR20180066039A (ko) | 아파티닙을 포함하는 약학적 조성물 | |
| WO2018069937A1 (en) | Solid dispersions of trisodium sacubitril valsartan and process for the preparation thereof | |
| US20180271890A1 (en) | Solid Pharmaceutical Composition Comprising Amorphous Sofosbuvir | |
| JP2009527577A (ja) | フルバスタチンナトリウム医薬組成物 | |
| WO2007061415A1 (en) | Pharmaceutical compositions of telmisartan | |
| EP3860606A1 (en) | Pharmaceutical composition comprising lenvatinib esylate or tosylate | |
| EP2694036A1 (en) | Pharmaceutical composition comprising fesoterodine | |
| WO2017211779A1 (en) | Pharmaceutical compositions of betrixaban maleate | |
| KR101446129B1 (ko) | 프란루카스트-함유 고형 제제의 제조방법 | |
| KR20100083047A (ko) | 생체이용률이 향상된 발사르탄을 포함하는 약제학적 조성물 | |
| KR20190038881A (ko) | 무정형 소포스부비르를 포함하는 고체 제약 조성물 | |
| WO2011129792A1 (en) | Water dispersible formulations comprising cefpodoxime proxetil | |
| KR101617119B1 (ko) | 셀레콕시브를 포함하는 경구용 정제의 제조방법 | |
| JP2009521518A (ja) | 無水オランザピンｉ型の経口処方物 | |
| KR100591786B1 (ko) | 프란루카스트를 함유하는 약학적 조성물 및 이의 제조 방법 | |
| JP2023054766A (ja) | アピキサバン含有粒子、それを含む医薬組成物、及びそれらの製造方法 | |
| WO2019030387A1 (en) | SOLID COMPOSITION COMPRISING AMORPHOUS SOFOSBUVIR AND AMORPHOUS DACLATASVIR | |
| WO2019172420A1 (ja) | 医薬組成物 | |
| WO2011161504A1 (en) | Extended release formulations containing darifenacin or pharmaceutically acceptable salts thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20161123 |
|
| WW01 | Invention patent application withdrawn after publication |